Abstract
Variation in the CYP3A enzymes, which act in drug metabolism, influences circulating steroid levels and responses to half of all oxidatively metabolized drugs. CYP3A activity is the sum activity of the family of CYP3A genes, including CYP3A5, which is polymorphically expressed at high levels in a minority of Americans of European descent and Europeans (hereafter collectively referred to as 'Caucasians'). Only people with at least one CYP3A5*1 allele express large amounts of CYP3A5. Our findings show that single-nucleotide polymorphisms (SNPs) in CYP3A5*3 and CYP3A5*6 that cause alternative splicing and protein truncation result in the absence of CYP3A5 from tissues of some people. CYP3A5 was more frequently expressed in livers of African Americans (60%) than in those of Caucasians (33%). Because CYP3A5 represents at least 50% of the total hepatic CYP3A content in people polymorphically expressing CYP3A5, CYP3A5 may be the most important genetic contributor to interindividual and interracial differences in CYP3A-dependent drug clearance and in responses to many medicines.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lander, E.S. et al. Initial sequencing and analysis of the human genome. Nature 409, 860–921 (2001).
Venter, J.C. et al. The sequence of the human genome. Science 291, 1304–1351 (2001).
Collins, F.S., Brooks, L.D. & Chakravarti, A. A DNA polymorphism discovery resource for research on human genetic variation. Genome Res. 8, 1229–1231 (1998).
Collins, F.S., Guyer, M.S. & Chakravarti, A. Variations on a theme: cataloging human DNA sequence variation. Science 278, 1580–1581 (1997).
Evans, W.E. & Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487–491 (1999).
Rendic, S. & DiCarlo, F.J. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 29, 413–580 (1997).
Cholerton, S., Daly, A.K. & Idle, J.R. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol. Sci. 13, 434–439 (1992).
Shimada, T., Yamazake, H., Mimura, M., Inui, Y. & Guengerich, F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414–423 (1994).
Watkins, P.B. Cyclosporine and liver transplantation: will the midazolam test make blood level monitoring obsolete? Hepatology 22, 994–996 (1995).
Kivisto, K.T., Koremer, H.K. & Eichelbaum, M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br. J. Clin. Pharmacol. 40, 523–530 (1995).
Huang, Z., Guengerich, F.P. & Kaminsky, L.S. 16α-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis 19, 867–872 (1998).
Finta, C. & Zaphiropoulos, P.G. The human cytochrome P4503A locus. Gene evolution by capture of downstream exons. Gene 260, 13–23 (2000).
Schuetz, J.D., Beach, D.L. & Guzelian, P.S. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4, 11–20 (1994).
Wrighton, S.A., Ring, B.J., Watkins, P.B. & Vandenbranden, M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol. Pharmacol. 36, 97–105 (1989).
Schuetz, J.D., Molowa, D.T. & Guzelian, P.S. Characterisation of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver. Arch. Biochem. Biophys. 274, 355–365 (1989).
Paine, M.F. et al. Characterization of interintestinal and intrainestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther. 283, 1552–1562 (1997).
Paulussen, A. et al. Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 10, 415–424 (2000).
Lehmann, J.M. et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102, 1–8 (1998).
Blumberg, B. et al. SXR, a novel steroid and xenobiotic sensing nuclear receptor. Genes Dev. 12, 3195–3205 (1998).
Rebbeck, T.R., Jaffe, J.A., Walker, A.H., Wein, A.J. & Malkowicz, S.B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 90, 1225–1229 (1998).
Gonzalez, F.J. The molecular biology of cytochrome P450s. Pharmacol. Rev. 40, 243–288 (1989).
Sata, F. et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther. 67, 48–56 (2000).
Goodwin, B.J., Hodgson, E. & Liddle, C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56, 1329–1339 (1999).
Aoyama, T. et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J. Biol. Chem. 264, 10388–10395 (1989).
Maquat, L.E. When cells stop making sense: effects of nonsense codons on mRNA metabolism in vertebrate cells. RNA 1, 453–465 (1995).
Maquat, L.E. The power of point mutations. Nature Genet. 27, 5 (2001).
Jounaidi, Y., Hyrailles, V., Gervot, L. & Maurel, P. Detection of a CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Biochem. Biophys. Res. Commun. 221, 466–470 (1996).
Gorski, J.C., Hall, S.D., Jones, D.R., BandenBranden, M. & Wrighton, S.A. Regioselective biotransformation of midazolam by members of the human cytochrome P4503A (CYP3A) subfamily. Biochem. Pharm. 47, 1643–1653 (1994).
Felix, C.A. et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. USA 95, 13176–13181 (1998).
Paris, P.L. et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol. Biomarkers Prev. 8, 901–905 (1999).
Westlind, A., Lofberg, L., Tindberg, N., Andersson, T.B. & Ingelman-Sundberg, M. Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem. Biophys. Res. Commun. 259, 201–205 (1999).
Ball, S.E. et al. Population disribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin. Pharmacol. Ther. 66, 288–294 (1999).
Hashimoto, H. et al. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur. J. Biochem. 218, 585–595 (1993).
Cooper, T.A. & Mattox, W. The regulation of splice-site selection, and its role in human disease. Am. J. Hum. Genet. 61, 259–266 (1997).
Wrighton, S.A. et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38, 207–213 (1990).
Gillam, E.M.J. et al. Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch. Biochem. Biophys. 317, 374–384 (1995).
Grogan, W.M., Phillips, V.M., Schuetz, E.G., Guzelian, P.S. & Watlington, C.O. Corticosterone 6b-hydroxylase in A6 epithelia: a steroid-inducible cytochrome P-450. Am. J. Physiol. Cell Physiol. 258, C480–C488 (1990).
Schuetz, E.G. et al. Expression of cytochrome P4503A in amphibian, rat and human kidney. Arch. Biochem. Biophys. 294, 206–214 (1992).
Haehner, B.D. et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol. Pharmacol. 50, 52–59 (1996).
Halushka, M.K. et al. Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nature Genet. 22, 239–247 (1999).
Cargill, M. et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nature Genet 22, 231–238 (1999).
Nickerson, D.A., Tobe, V.O. & Taylor, S.L. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res. 25, 2745–2751 (1997).
Schuetz, E.G., Beck, W.T. & Schuetz, J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 49, 311–318 (1996).
Nebert, D.W. Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology. Pharmacogenetics 10, 279–290 (2000).
Acknowledgements
We thank E. Green for advice and use of facilities. This work was supported in part by grant GM60346 and the NIH/NIGMS Pharmacogenetics Research Network and Database (U01GM61374, http://pharmgkb.org/) under grant U01GM (GM61393) and by grants GM32165, ES08658, P30 CA21765, and CA51001 from the National Institutes of Health and by the American Lebanese Syrian Associated Charities (ALSAC).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kuehl, P., Zhang, J., Lin, Y. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27, 383–391 (2001). https://doi.org/10.1038/86882
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/86882
This article is cited by
-
Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes
Malaria Journal (2023)
-
Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy
Cancer Chemotherapy and Pharmacology (2023)
-
Evaluation of UGT1A1 and CYP3A Genotyping and Single-Point Irinotecan and Metabolite Concentrations as Predictors of the Occurrence of Adverse Events in Cancer Treatment
Journal of Gastrointestinal Cancer (2023)
-
Role of pharmacogenetics and tacrolimus dosing in liver transplantation
Hepatology International (2023)
-
The prevalence of pharmacogenetic variants of vitamin K epoxide reductase complex subunit 1 gene (rs9923231), cytochrome P450 family 2 subfamily C member 9 gene (rs1799853) and cytochrome P450 family 3 subfamily-A member-5 gene (rs776746) among 13 ethnic groups of Pakistan
Molecular Biology Reports (2023)